Cargando…

Gelatin-coated silicon oxide nanoparticles encapsulated recombinant human secretory leukocyte protease inhibitor (rhSLPI) reduced cardiac cell death against an in vitro simulated ischaemia/reperfusion injury

Ischemic Heart Disease (IHD) is the main global cause of death. Previous studies indicated that recombinant human secretory leukocyte protease inhibitor (rhSLPI) exhibits a cardioprotective effect against myocardial ischaemia/reperfusion (I/R) injury. However, SLPI has a short half-life in vivo due...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pikwong, Faprathan, Phutiyothin, Chayanisa, Chouyratchakarn, Wannapat, Baipaywad, Phornsawat, Mongkolpathumrat, Podsawee, Kumphune, Sarawut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559932/ https://www.ncbi.nlm.nih.gov/pubmed/37809945 http://dx.doi.org/10.1016/j.heliyon.2023.e20150

Ejemplares similares

Adeno-associated virus 9 vector-mediated cardiac-selective expression of human secretory leukocyte protease inhibitor attenuates myocardial ischemia/reperfusion injury
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2022)

Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2021)

Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2022)

Endothelial-Cell-Derived Human Secretory Leukocyte Protease Inhibitor (SLPI) Protects Cardiomyocytes against Ischemia/Reperfusion Injury
por: Kongpol, Kantapich, et al.
Publicado: (2019)

An in vitro endothelial cell protective effect of secretory leukocyte protease inhibitor against simulated ischaemia/reperfusion injury
por: Nernpermpisooth, Nitirut, et al.
Publicado: (2017)

Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats
por: Sanit, Jantira, et al.
Publicado: (2019)

Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.
por: Nyström, M, et al.
Publicado: (1999)

Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
por: Dickey, Brittney L., et al.
Publicado: (2021)

Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice
por: Nakamura, Akira, et al.
Publicado: (2003)

How SLPI soothes
por: Van Epps, Heather L.
Publicado: (2005)

Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression
por: Wex, Thomas, et al.
Publicado: (2011)

Increased Secretory Leukocyte Protease Inhibitor (SLPI) Production by Highly Metastatic Mouse Breast Cancer Cells
por: Sayers, Kevin T., et al.
Publicado: (2014)

The cardioprotective effects of secretory leukocyte protease inhibitor against myocardial ischemia/reperfusion injury
por: Prompunt, Eakkapote, et al.
Publicado: (2018)

Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers
por: Kozin, Sergey V., et al.
Publicado: (2017)

Recent biomedical advancements in graphene oxide- and reduced graphene oxide-based nanocomposite nanocarriers
por: Bellier, Naline, et al.
Publicado: (2022)

Secretory Leukocyte Protease Inhibitor (SLPI) Is, like Its Homologue Trappin-2 (Pre-Elafin), a Transglutaminase Substrate
por: Baranger, Kévin, et al.
Publicado: (2011)

Plasma concentrations of secretory leukocyte protease inhibitor (SLPI) differ depending on etiology and severity in community-onset bloodstream infection
por: Lange, Anna, et al.
Publicado: (2019)

Secretory Leukoprotease Inhibitor (Slpi) Expression Is Required for Educating Murine Dendritic Cells Inflammatory Response Following Quercetin Exposure
por: De Santis, Stefania, et al.
Publicado: (2017)

Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells
por: Wei, Zhijiang, et al.
Publicado: (2023)

Cementoin–SLPI fusion protein binds to human monocytes and epithelial cells and shows higher biological activity than SLPI
por: Maffía, Paulo C., et al.
Publicado: (2018)

Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex
por: Sullivan, Anita L, et al.
Publicado: (2008)

Targeting secretory leukocyte protease inhibitor (SLPI) inhibits colorectal cancer cell growth, migration and invasion via downregulation of AKT
por: Wei, Zhijiang, et al.
Publicado: (2020)

SLPI: a new target for stopping metastasis
por: Munn, Lance L., et al.
Publicado: (2018)

IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release.
por: Westin, U, et al.
Publicado: (1998)

Secretory Leucoprotease Inhibitor (SLPI) Promotes Survival during Acute Pseudomonas aeruginosa Infection by Suppression of Inflammation Rather Than Microbial Killing
por: Osbourn, Megan, et al.
Publicado: (2022)

High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence
por: Nugteren, Sandrine, et al.
Publicado: (2022)

Complex of human neutrophil elastase with 1/2SLPI
por: Koizumi, Masahiro, et al.
Publicado: (2008)

Single-step acid-catalyzed synthesis of luminescent colloidal organosilica nanobeads
por: Baipaywad, Phornsawat, et al.
Publicado: (2022)

Composite Nanocellulose Fibers-Based Hydrogels Loading Clindamycin HCl with Ca(2+) and Citric Acid as Crosslinking Agents for Pharmaceutical Applications
por: O-chongpian, Pichapar, et al.
Publicado: (2021)

Correction: Single-step acid-catalyzed synthesis of luminescent colloidal organosilica nanobeads
por: Baipaywad, Phornsawat, et al.
Publicado: (2022)

Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis
por: Nugteren, Sandrine, et al.
Publicado: (2020)

Secretory Leukocyte Protease Inhibitor (SLPI)—A Novel Predictive Biomarker of Acute Kidney Injury after Cardiac Surgery: A Prospective Observational Study
por: Averdunk, Luisa, et al.
Publicado: (2019)

Facile preparation of poly(N-isopropylacrylamide)/graphene oxide nanocomposites for chemo-photothermal therapy
por: Baipaywad, Phornsawat, et al.
Publicado: (2022)

Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis
por: Müller, André Michael, et al.
Publicado: (2012)

Automatic Programmable Bioreactor with pH Monitoring System for Tissue Engineering Application
por: Udomsom, Suruk, et al.
Publicado: (2022)

Structure basis 1/2SLPI and porcine pancreas trypsin interaction
por: Fukushima, Kei, et al.
Publicado: (2013)

SLPI knockdown induced pancreatic ductal adenocarcinoma cells proliferation and invasion
por: Zhang, Wei, et al.
Publicado: (2015)

SLPI is a critical mediator that controls PTH-induced bone formation
por: Morimoto, Akito, et al.
Publicado: (2021)

Reduced ELANE and SLPI expression compromises dental pulp cell activity
por: Sriwattanapong, Kanokwan, et al.
Publicado: (2021)

Editorial: New Strategies to Inhibit Cell Death in Myocardial Ischemia-Reperfusion Injury: How to Succeed?
por: Barrère-Lemaire, Stéphanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9lnll580vgtpovm8jqo6igpqvo